MX380779B - Terapia combinatoria con inhibidores notch y cdk4/6 - Google Patents
Terapia combinatoria con inhibidores notch y cdk4/6Info
- Publication number
- MX380779B MX380779B MX2018012457A MX2018012457A MX380779B MX 380779 B MX380779 B MX 380779B MX 2018012457 A MX2018012457 A MX 2018012457A MX 2018012457 A MX2018012457 A MX 2018012457A MX 380779 B MX380779 B MX 380779B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- oxo
- fluoro
- ethyl
- methyl
- Prior art date
Links
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 abstract 2
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010059352 Desmoid tumour Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000000172 Medulloblastoma Diseases 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 abstract 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 abstract 1
- 201000006827 desmoid tumor Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662321311P | 2016-04-12 | 2016-04-12 | |
| PCT/US2017/026134 WO2017180389A1 (en) | 2016-04-12 | 2017-04-05 | Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012457A MX2018012457A (es) | 2019-03-07 |
| MX380779B true MX380779B (es) | 2025-03-12 |
Family
ID=58548919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012457A MX380779B (es) | 2016-04-12 | 2017-04-05 | Terapia combinatoria con inhibidores notch y cdk4/6 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11298362B2 (enExample) |
| EP (1) | EP3442529B1 (enExample) |
| JP (2) | JP6911047B2 (enExample) |
| KR (1) | KR102418765B1 (enExample) |
| CN (1) | CN109310684B (enExample) |
| AU (1) | AU2017249078B2 (enExample) |
| CA (1) | CA3020875A1 (enExample) |
| ES (1) | ES2881801T3 (enExample) |
| MX (1) | MX380779B (enExample) |
| RU (1) | RU2747788C2 (enExample) |
| WO (1) | WO2017180389A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| AU2017249078B2 (en) | 2016-04-12 | 2022-10-20 | Eli Lilly And Company | Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer |
| MX380780B (es) * | 2016-04-12 | 2025-03-12 | Lilly Co Eli | TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR. |
| US10688104B2 (en) | 2016-05-20 | 2020-06-23 | Eli Lilly And Company | Combination therapy with Notch and PD-1 or PD-L1 inhibitors |
| CA3039405A1 (en) | 2016-10-12 | 2018-04-19 | Eli Lilly And Company | Targeted treatment of mature t-cell lymphoma |
| CN110461335A (zh) | 2017-02-17 | 2019-11-15 | 弗雷德哈钦森癌症研究中心 | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 |
| US12193994B2 (en) | 2017-11-06 | 2025-01-14 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| IL257225A (en) * | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
| AU2019266150A1 (en) * | 2018-05-06 | 2021-01-07 | Ayala Pharmaceuticals Inc. | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof |
| WO2019226667A1 (en) * | 2018-05-25 | 2019-11-28 | Nantomics, Llc | Comprehensive molecular profiling with proteomic and genomic analyses |
| CN112535686B (zh) * | 2019-09-20 | 2022-06-14 | 山东轩竹医药科技有限公司 | 激酶抑制剂的新用途 |
| CN113880809B (zh) * | 2020-07-03 | 2022-10-18 | 盛世泰科生物医药技术(苏州)有限公司 | 一种嘧啶类衍生物及其制备方法和应用 |
| WO2023109875A1 (en) * | 2021-12-16 | 2023-06-22 | Edigene Therapeutics (Beijing) Inc. | Biomarkers for colorectal cancer treatment |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP970705A2 (en) | 1996-12-23 | 1998-10-31 | Warren J. Porter | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS |
| AU768269B2 (en) | 1998-10-02 | 2003-12-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Apoptosis inducing agents and methods |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| US8633179B2 (en) | 2007-03-13 | 2014-01-21 | The Trustees Of Columbia University In The City Of New York | Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids |
| BRPI0815135A2 (pt) | 2007-08-14 | 2015-02-03 | Lilly Co Eli | Derivados de azepina como inibidores de gama secretase. |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| WO2011060051A1 (en) | 2009-11-12 | 2011-05-19 | University Of Massachusetts | Methods for treating glioblastoma |
| CN102085372A (zh) | 2009-12-04 | 2011-06-08 | 中国医学科学院基础医学研究所 | Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| JO3148B1 (ar) | 2011-07-27 | 2017-09-20 | Lilly Co Eli | مركب مثبط لإشارات مسار notch |
| JP6720075B2 (ja) | 2013-05-31 | 2020-07-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 癌のための併用療法 |
| JP6586087B2 (ja) | 2013-08-20 | 2019-10-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療 |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| EP3280795B1 (en) | 2015-04-07 | 2021-03-24 | Novartis AG | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| MX380780B (es) | 2016-04-12 | 2025-03-12 | Lilly Co Eli | TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR. |
| AU2017249078B2 (en) | 2016-04-12 | 2022-10-20 | Eli Lilly And Company | Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer |
| US10688104B2 (en) | 2016-05-20 | 2020-06-23 | Eli Lilly And Company | Combination therapy with Notch and PD-1 or PD-L1 inhibitors |
| CN109562114A (zh) | 2016-08-31 | 2019-04-02 | 伊莱利利公司 | 用于治疗实体瘤的给药方案 |
| CA3039405A1 (en) | 2016-10-12 | 2018-04-19 | Eli Lilly And Company | Targeted treatment of mature t-cell lymphoma |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| US12193994B2 (en) | 2017-11-06 | 2025-01-14 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
-
2017
- 2017-04-05 AU AU2017249078A patent/AU2017249078B2/en active Active
- 2017-04-05 CA CA3020875A patent/CA3020875A1/en active Pending
- 2017-04-05 MX MX2018012457A patent/MX380779B/es unknown
- 2017-04-05 ES ES17717990T patent/ES2881801T3/es active Active
- 2017-04-05 CN CN201780036170.7A patent/CN109310684B/zh active Active
- 2017-04-05 US US16/093,123 patent/US11298362B2/en active Active
- 2017-04-05 WO PCT/US2017/026134 patent/WO2017180389A1/en not_active Ceased
- 2017-04-05 EP EP17717990.0A patent/EP3442529B1/en active Active
- 2017-04-05 KR KR1020187032285A patent/KR102418765B1/ko active Active
- 2017-04-05 RU RU2018138627A patent/RU2747788C2/ru active
- 2017-04-05 JP JP2018553357A patent/JP6911047B2/ja not_active Expired - Fee Related
-
2021
- 2021-07-07 JP JP2021112726A patent/JP7288482B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2747788C2 (ru) | 2021-05-14 |
| AU2017249078B2 (en) | 2022-10-20 |
| WO2017180389A1 (en) | 2017-10-19 |
| EP3442529B1 (en) | 2021-05-26 |
| RU2018138627A (ru) | 2020-05-12 |
| ES2881801T3 (es) | 2021-11-30 |
| CN109310684B (zh) | 2021-11-19 |
| KR102418765B1 (ko) | 2022-07-08 |
| US11298362B2 (en) | 2022-04-12 |
| CA3020875A1 (en) | 2017-10-19 |
| RU2018138627A3 (enExample) | 2020-06-10 |
| EP3442529A1 (en) | 2019-02-20 |
| AU2017249078A1 (en) | 2018-11-01 |
| MX2018012457A (es) | 2019-03-07 |
| CN109310684A (zh) | 2019-02-05 |
| JP7288482B2 (ja) | 2023-06-07 |
| KR20180129918A (ko) | 2018-12-05 |
| JP6911047B2 (ja) | 2021-07-28 |
| JP2019511526A (ja) | 2019-04-25 |
| JP2021176858A (ja) | 2021-11-11 |
| US20210213029A1 (en) | 2021-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX380779B (es) | Terapia combinatoria con inhibidores notch y cdk4/6 | |
| MX380780B (es) | TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR. | |
| ZA201807585B (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| ZA202303450B (en) | Indole derivatives as ras inhibitors in the treatment of cancer | |
| MX381475B (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
| NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| NZ589269A (en) | Combination therapy with an antitumor alkaloid | |
| EA200801671A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| PH12019500892A1 (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) | |
| BR112018002941A2 (pt) | métodos para tratar câncer pancreático metastático usando terapias de combinação compreendendo irinotecano lipossomal e oxaliplatina | |
| ZA201806684B (en) | Methods of treating pediatric cancers | |
| MX2009007597A (es) | Terapia especifica y medicamento que utilizan ligandos de integrina para tratar el cancer. | |
| MX2022009612A (es) | Combinacion de bi853520 con farmacos quimioterapeuticos. | |
| NZ726365A (en) | Combinations for treating cancers | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| RU2005102836A (ru) | Терапевтические комбинации ингибиторов erbb-киназ и противоопухолевые способы лечения | |
| EA202092008A1 (ru) | Противораковые фармацевтические композиции для комплексной терапии | |
| Eskander et al. | Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise | |
| WO2014115859A3 (ja) | 分子標的併用腫瘍治療・予防薬 | |
| HK1259409A1 (zh) | 酪蛋白激酶1δ在乳腺癌中的治疗靶向 | |
| RU2010119922A (ru) | Усовершенствованное противоопухолевое лечение | |
| JP2011500723A5 (enExample) | ||
| NZ742470A (en) | Combination therapy for cancer | |
| NZ795045B2 (en) | Compound for the treatment of braf-associated diseases and disorders |